Combination of | |
---|---|
Lamivudine | nucleoside reverse transcriptase inhibitor |
Nevirapine | non-nucleoside reverse transcriptase inhibitor |
Stavudine | nucleoside reverse transcriptase inhibitor |
Clinical data | |
Trade names | Triomune, others |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] It contains lamivudine, nevirapine, and stavudine. [1] It is either used by itself or along with other antiretrovirals. [1] It is taken by mouth twice a day. [1]
It is on the World Health Organization's List of Essential Medicines. [2] As of 2015, it is not commercially available in the United States. [3]
It is a common first line treatment in the developing world. [4]
The medication is generally well tolerated. [5] Side effects are those of the underlying medications. [1] This may include rash, numbness, pancreatitis, and high blood lactate levels. [5] Use is not recommended in those with significant liver problems. [5] It is unclear if use in pregnancy is safe for the baby and recommendations include starting in the second trimester if possible. [5]